By Use Case Stubborn Fat Reduction Timeline: 6-12 weeks for visible changes Best approach: 300mcg fasted, consistent caloric deficit, fasted cardio Realistic expectation: 4-8 lbs additional fat loss over 12 weeks vs diet alone Body Recomposition (Stacked) Timeline: 4-8 weeks for synergistic effects Common stacks: AOD-9604 + CJC-1295/Ipamorelin for GH-enhanced fat loss, or AOD-9604 + low-dose semaglutide for appetite control + enhanced fat oxidation Realistic expectation: Faster results than AOD-9604 alone, but more variables to manage Post-GLP-1 Transition Timeline: Begin immediately after tapering off semaglutide or tirzepatide Purpose: Maintain fat oxidation support while transitioning away from appetite-suppressing peptides Realistic expectation: May help prevent rebound weight gain by sustaining lipolytic activity, though this is community-reported, not clinically studied When to Adjust Protocol Signs it's working: Gradual but consistent downward trend in waist measurement Clothes fitting differently even if scale weight is stable Improved fasted cardio endurance Better body composition in progress photos at 6+ weeks Signs to reassess: Zero measurable change by week 8 with optimized timing and deficit No subjective difference in energy or body composition Side effects (rare but worth noting: headache, nausea) If it's not working: Verify fasted injection timing (no food 1-2 hours before or after) Confirm caloric deficit (track intake for 2 weeks) Consider increasing to 500mcg/day Evaluate whether a different mechanism (GLP-1, GH secretagogue) would be more appropriate for the goal Research Supplies for AOD-9604 Hand-picked storage, injection, and recovery supplies paired with AOD-9604 protocols
The right panel displays a hydrogen bond between Thr 12 of Lsm6 and Asp 38 of Lsm5 and van der Waals contact between Val 11 of Lsm6 and Ile 44 of Lsm5
When the committee looked at the actual evidence, the science spoke for itself
Curcumin also induced a reduction in plasma concentrations of inflammatory markers and an increase in plasma concentrations of brain-derived neurotrophic factor compared to placebo (antidepressant drug alone) (104)
